Grima Natalie A, Rajaratnam Shantha M W, Mansfield Darren, McKenzie Dean, Ponsford Jennie L
Monash-Epworth Rehabilitation Research Centre, Epworth HealthCare, Richmond, Victoria, Australia.
Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria, Australia.
J Clin Sleep Med. 2021 Aug 1;17(8):1545-1551. doi: 10.5664/jcsm.9234.
A recent clinical trial demonstrated that melatonin treatment was effective in improving self-perceived sleep quality in patients with traumatic brain injury (TBI); however, it remains unclear which patients benefited from melatonin treatment. To that end, findings from the clinical trial were re-examined to identify possible predictors of treatment response.
Hierarchical multiple regression was used to identify patient characteristics, TBI injury characteristics, and self-report measures assessing sleep, fatigue, mood, and anxiety symptomatology that may uniquely explain a change in self-reported sleep quality scores (follow-up minus baseline score) as assessed by the Pittsburgh Sleep Quality Index (PSQI).
After controlling for patient demographic and TBI injury-related variables, baseline self-report measures of sleep, fatigue, mood, and anxiety explained an additional 32% of the variance in change in PSQI scores. However, only baseline PSQI score made a unique and statistically significant contribution (β = -0.56, = .006). After controlling for patient and TBI characteristics, baseline PSQI scores further explained 27% of the variance in change in PSQI scores ( change = .27, change = 11.79, = .002). The standardized β for baseline PSQI score revealed a statistically significant negative relationship with change in PSQI score (β = -0.54, = .002), revealing that higher PSQI score at baseline was associated with better sleep outcomes.
In a sample comprising predominantly severe TBI and comorbid insomnia, participants who report poorer sleep quality have the most to gain from melatonin treatment irrespective of time since injury, demographics, fatigue, daytimes sleepiness, mood, and anxiety symptomology.
Registry: Australian New Zealand Clinical Trials Registry; Name: Efficacy of Melatonin for Sleep Disturbance Following Traumatic Brain Injury; URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=343083&showOriginal=true&isReview=true; Identifier: ACTRN12611000734965.
Grima NA, Rajaratnam SMW, Mansfield D, McKenzie D, Ponsford JL. Poorer sleep quality predicts melatonin response in patients with traumatic brain injury: findings from a randomized controlled trial. 2021;17(8):1545-1551.
最近一项临床试验表明,褪黑素治疗对改善创伤性脑损伤(TBI)患者自我感知的睡眠质量有效;然而,仍不清楚哪些患者从褪黑素治疗中获益。为此,重新审视了该临床试验的结果,以确定治疗反应的可能预测因素。
采用分层多元回归来确定患者特征、TBI损伤特征以及评估睡眠、疲劳、情绪和焦虑症状的自我报告指标,这些指标可能独特地解释匹兹堡睡眠质量指数(PSQI)评估的自我报告睡眠质量得分变化(随访得分减去基线得分)。
在控制了患者人口统计学和TBI损伤相关变量后,睡眠、疲劳、情绪和焦虑的基线自我报告指标又解释了PSQI得分变化中32%的方差。然而,只有基线PSQI得分做出了独特且具有统计学意义的贡献(β = -0.56,P = .006)。在控制了患者和TBI特征后,基线PSQI得分进一步解释了PSQI得分变化中27%的方差(R²变化 = .27,F变化 = 11.79,P = .002)。基线PSQI得分的标准化β显示与PSQI得分变化存在统计学显著的负相关(β = -0.54,P = .002),表明基线时较高的PSQI得分与更好的睡眠结果相关。
在一个主要包括重度TBI和共病失眠的样本中,报告睡眠质量较差的参与者无论受伤时间、人口统计学、疲劳、日间嗜睡、情绪和焦虑症状如何,从褪黑素治疗中获益最大。
注册机构:澳大利亚和新西兰临床试验注册中心;名称:创伤性脑损伤后褪黑素对睡眠障碍的疗效;网址:https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=343083&showOriginal=true&isReview=true;标识符:ACTRN12611000734965。
Grima NA, Rajaratnam SMW, Mansfield D, McKenzie D, Ponsford JL. 较差的睡眠质量可预测创伤性脑损伤患者对褪黑素的反应:一项随机对照试验的结果。2021;17(8):1545 - 1551。